Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040623 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
A Phase 2 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02040623: Completed Phase 2 study, sponsored by Rigel Pharmaceuticals.
NCT02040623 is a Phase 2 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02040623, a Phase 2 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
* To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. * To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.
Primary Outcome
Change from baseline (Visit 1) of total CFS score at 12 weeks. Total CFS score range 0-20, where '0' represents no fluorescein staining of any region and '20' represents severe staining the entire cornea.
Interventions
- DRUG R348 Ophthalmic Solution, 0.2%
- DRUG R348 Ophthalmic Solution, 0.5%
- OTHER Placebo Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
What the finished NCT02040623 record still lists
NCT02040623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which R348 Ophthalmic Solution, 0.2% is the first listed.
NCT02040623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02040623 about?
NCT02040623 is a clinical study titled "Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)". * To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. * To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.
What is the current status of trial NCT02040623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2014-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02040623?
The interventions under investigation include: R348 Ophthalmic Solution, 0.2% (DRUG), R348 Ophthalmic Solution, 0.5% (DRUG), Placebo Ophthalmic Solution (OTHER).
Who is sponsoring clinical trial NCT02040623?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02040623's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia